Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

232 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Consensus guidelines for the management and treatment of neuroendocrine tumors.
Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, Chen H, Jensen RT, Kim MK, Klimstra DS, Kulke MH, Liu EH, Metz DC, Phan AT, Sippel RS, Strosberg JR, Yao JC; North American Neuroendocrine Tumor Society. Kunz PL, et al. Among authors: kulke mh. Pancreas. 2013 May;42(4):557-77. doi: 10.1097/MPA.0b013e31828e34a4. Pancreas. 2013. PMID: 23591432 Free PMC article.
Progress in the treatment of neuroendocrine tumors.
Chan JA, Kulke MH. Chan JA, et al. Among authors: kulke mh. Curr Oncol Rep. 2009 May;11(3):193-9. doi: 10.1007/s11912-009-0028-0. Curr Oncol Rep. 2009. PMID: 19336011 Free PMC article. Review.
NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors.
Clark OH, Benson AB 3rd, Berlin JD, Choti MA, Doherty GM, Engstrom PF, Gibbs JF, Heslin MJ, Kessinger A, Kulke MH, Kvols L, Salem R, Saltz L, Shah MH, Shibata S, Strosberg JR, Yao JC; NCCN Neuroendocrine Tumors Panel Members. Clark OH, et al. Among authors: kulke mh. J Natl Compr Canc Netw. 2009 Jul;7(7):712-47. doi: 10.6004/jnccn.2009.0050. J Natl Compr Canc Netw. 2009. PMID: 19635226 No abstract available.
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.
Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O'Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B. Yao JC, et al. Among authors: kulke mh. J Clin Oncol. 2010 Jan 1;28(1):69-76. doi: 10.1200/JCO.2009.24.2669. Epub 2009 Nov 23. J Clin Oncol. 2010. PMID: 19933912 Free PMC article. Clinical Trial.
Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set.
Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, Gönen M, Jensen RT, Kidd M, Kulke MH, Lloyd RV, Moran C, Moss SF, Oberg K, O'Toole D, Rindi G, Robert ME, Suster S, Tang LH, Tzen CY, Washington MK, Wiedenmann B, Yao J. Klimstra DS, et al. Among authors: kulke mh. Am J Surg Pathol. 2010 Mar;34(3):300-13. doi: 10.1097/PAS.0b013e3181ce1447. Am J Surg Pathol. 2010. PMID: 20118772
Phase II study of pemetrexed in patients with advanced neuroendocrine tumors.
Chan JA, Zhu AX, Stuart K, Bhargava P, Earle CC, Clark JW, Casey C, Regan E, Kulke MH. Chan JA, et al. Among authors: kulke mh. Cancer Chemother Pharmacol. 2010 Oct;66(5):961-8. doi: 10.1007/s00280-010-1248-6. Epub 2010 Feb 4. Cancer Chemother Pharmacol. 2010. PMID: 20130879 Free PMC article. Clinical Trial.
232 results